Abstract

The aim of this study was to review the antimalarial drug treatment and its resistance during the course of therapy. Malaria affects the populations of tropical and subtropical areas world-wide, as well as an increasing number of travellers to these areas. Although malaria is found in over 100 countries, the major burden of disease is carried by the nations of Africa, where over 90% of all deaths from falciparum malaria are recorded and where the high levels of morbidity and transmission place considerable strains on public health services and economic infrastructure. In the absence of effective vaccines, management of the disease has depended largely upon chemotherapy and chemoprophylaxis. The number of available and effective antimalarial drugs is quickly dwindling due to different cause. This is mainly because a number of drug resistance-associated mutations in malaria parasite genes, such as crt, mdr1, dhfr/dhps and others, have led to widespread resistance to all known classes of antimalarial compounds. Unfortunately, malaria parasites have started to exhibit some level of resistance in Southeast Asia even to the most recently introduced class of drugs, artemisinins. Molecular evolutionary and population genetic approaches will greatly facilitate our understanding of the evolution and spread of parasite drug resistance and will contribute to developing strategies for better control of malaria. While there is much need, the antimalarial drug development pipeline remains woefully thin, with little chemical diversity and there is currently no alternative to the precious artemisinins. In general, four basic methods have been routinely used to study or measure antimalarial drug resistance: in vivo, in vitro, animal model studies and molecular characterization. This review endeavors to present the background facts and treatment and more on the current status of antimalarial drug resistance, what their causes, mechanisms, spread and management are and future perspective with antimalarial treatment. Furthermore, findings from this review will be useful to clinical researchers, health planners, policy makers and stakeholders and others concerned for malaria patients.

Keywords:

Detection of resistance, drug resistance, malaria, mutation, p. falciparum, p.vivax,

References

1. Anvikar, A.R., B. Sharma, S.K. Sharma, S.K. Ghosh, R.M. Bhat, A. Kumar, S.S. Mohanty and C.R. Pillai, 2012. In vitro assessment of drug resistance in Plasmodium falciparum in five States of India. Indian J. Med. Res., 135: 494-499.
   PMid:22664496 PMCid:PMC3385232    
2. Aminake, M.N. and G. Pradel, 2013. Antimalarial drugs resistance in Plasmodium falciparum and the current strategies to overcome them. Microbial pathogens and strategies for combating them: science, technology and education (A. Méndez-Vilas, Ed.). © FORMATEX 2013.
   
3. Alene, G.D. and S. Bennett, 1996. Chloroquine resistance of Plasmodium falciparum malaria in Ethiopia and Eritrea. Trop. Med. Int. Health, 1: 810-815.
   CrossRef    PMid:8980594    
4. Austin, D.J. and R.M. Anderson, 1999. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Philos. Trans. R. Soc. Lond. B Biol. Sci., 354: 721-738.
   CrossRef    PMid:10365398 PMCid:PMC1692559    
5. Adugna, A., 2009. Malaria in Ethiopia. Retrieved form: http:// www. ethiodemo graphyandhealth. org. (Accessed on: July 2, 2014).
   Direct Link
6. Briolant, S., H. Bogreau, M. Gil, H. Bouchiba, E. Baret, R. Amalvict, C. Rogier and B. Pradines, 2012. The F423Y mutation in the pfmdr2 gene and mutations N51I, C59R and S108N in the pfdhfr gene are independently associated with pyrimethamine resistance in Plasmodium falciparum isolates. Antimicrob. Agents Chemother., 56: 2750-2752.
   CrossRef    PMid:22314533 PMCid:PMC3346656    
7. Batista, R., J.S. Junior and A.B. Oliveira, 2009. Plant derived antimalarial agents. Molecules, 14: 3037-3072.
   CrossRef    PMid:19701144    
8. Beith, A., 2008. Mapping Factors that Drive Drug Resistance (with a Focus on Resource-Limited Settings): A First Step towards Better Informed Policy. Retrieved form: www. cgdev. org/ drug_resistance. (Accessed on: August 2, 2014).
   Direct Link
9. Bauchner, H., S.I. Pelton and J.O. Klein, 1999. Parents, physicians and antibiotic use. Pediatrics., 103: 395-401.
   CrossRef    PMid:9925831    
10. Basco, L.K., 2007. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Switzerland, Geneva.
    PMCid:PMC2732998    
11. Bosman, A., C. Delacollette, P. Olumese, R.G. Ridley, A. Rietveld, R. Shretta and A. Teklehaimanot, 2001. The use of antimalarial drugs: Report of an Informal Consultation. Roll Back Malaria World Health Organization, Switzerland, 8.
    
12. Borrmann, S. and K. Matuschews, 2011. Targeting plasmodium liver stages: Better late than never. Trends Molecular Med., x: 1-10.
    CrossRef    
13. Charles, O.O., R.T. Walter, O. Bernhards, V. John and E.G. Diederick, 2000. Prevalence of and risk factors for malaria-associated anaemia in young Kenyan children. 5.
    
14. Costanzo, M.S. and D.L. Hartl, 2011. The evolutionary landscape of antifolate resistance in Plasmodium falciparum. J. Genet., 90: 187-190.
    CrossRef    PMid:21869466 PMCid:PMC3212943    
15. Cui, L. and X.Z. Su, 2009. Discovery, mechanisms of action and combination therapy of artemisinin. Exp. Rev. Anti-Infective Therap., 7(8): 999-1013.
    CrossRef    PMid:19803708 PMCid:PMC2778258    
16. CDC (Centers for Disease Control and Prevention), 2014. Global Health Strategy, 2012-2015.
    
17. Dondorp, A.M., F. Nosten, P. Yi, D. Das and A.P. Phyo, 2009. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 361: 455-467.
    CrossRef    PMid:19641202 PMCid:PMC3495232    
18. Daily, J.P., 2006. Antimalarial drug therapy: The role of parasite biology and drug resistance. J. Clin. Pharma., 46(12): 1487-1497.
    CrossRef    PMid:17101748    
19. Ding, X.C., H.P. Beck and G. Raso, 2011. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol., 27(2): 73-81.
    CrossRef    PMid:21169061    
20. Eyasu, M., W. Shibeshi and M. Giday, 2013. In vivo antimalarial activity of hydromethanolic leaf extract of Calpurnia aurea (Fabaceae) in Mice infected with chloroquine sensitive Plasmodium berghei. Int. J. Pharm. Pharmacol., 2(9): 131-142.
    
21. Foote, S.J., D. Galatis and A.F. Cowman, 1990. Amino acids in the dihydrofolate reductasethymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA, 87: 3014-3017.
    CrossRef    PMid:2183221 PMCid:PMC53824    
22. Fisher, N., R.A. Majid and T. Antoine, 2012. Cytochrome b mutation Y268S conferring the atovaquone resistance phenotype in the malaria parasite results in reduced parasite bc1 catalytic turnover and protein expression. The American Society for Biochemistry and Molecular Biology, Inc., Retrieved form: http://www.jbc.org/cgi/doi/ 10.1074/jbc.M111.324319. (Accessed on: June 12, 2014).
    Direct Link
23. Fairhurst, R.M., G.M. Nayyar, J.G. Breman, R. Hallett, J.L. Vennerstrom, S. Duong and P. Ringwald, 2012. Artemisinin-resistant malaria: Research challenges, opportunities and public health implications. Am. J. Trop. Med. Hyg., 87: 231-224.
    CrossRef    PMid:22855752 PMCid:PMC3414557    
24. Foley, M. and L. Tilley, 1997. Quinoline antimalarials: Mechanisms of action and resistance. Int. J. Parasitol., 27: 231-240.
    CrossRef    
25. Golenda, C.F., J. Li and R. Rosenberg, 1997. Continuous in vitro propagation of the malaria parasite Plasmodium vivax. Proceedings of the National Academy of Sciences of the United States of America, 94: 6786-6791.
    CrossRef    PMid:9192643 PMCid:PMC21236    
26. Gardiner, D.L., T.S. Skinner-Adams, C.L. Brown, K.T. Andrews, C.M. Stack, J.S. McCarthy, J.P. Dalton and K.R. Trenholme, 2009. Plasmodium falciparum: New molecular targets with potential for antimalarial drug development. Expert Rev. Anti Infect. Ther., 7(9): 1087-1098.
    CrossRef    PMid:19883329    
27. Gregson, A. and C. Plowe, 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev., 57: 117-145.
    CrossRef    PMid:15734729    
28. Grimberg, B.T. and R.K. Mehlotra 2011. Review on Expanding the Antimalarial Drug Arsenal-Now, But How? Retrieved form: www.mdpi.com/ journal/pharmaceuticals. (Accessed on: July 4, 2014).
    Direct Link
29. Hastings, I.M. and W.M. Watkins, 2006. Tolerance is the key to understanding antimalarial drug resistance. TRENDS in Parasitol., 22(2): 2-3.
    CrossRef    PMid:16406706    
30. Hyde, J.E., 2007. Drug-resistant malaria-An insight. FEBS J., 274: 4688-4698.
    CrossRef    PMid:17824955 PMCid:PMC2720519    
31. Hyde, J.E., 2002. Current focus Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infection, 4: 165-174.
    CrossRef    
32. Imwong, M., A.M. Dondorp, F. Nosten, P. Yi, M. Mungthin, S. Hanchana, D. Das and et al., 2010. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother., 54: 2886-2892.
    CrossRef    PMid:20421395 PMCid:PMC2897287    
33. Jain, P., B. Chakma, S. Patra and P. Goswami, 2014. Potential biomarkers and their applications for rapid and reliable detection of malaria. BioMed Res. Int., Retrieved form: http://dx.doi.org/10. 1155/2014/852645.
    Direct Link
34. Jones, M.K., Good, M.F., 2006. Life cycle of malaria in humans. Nature Medicine, 12: 170 - 171.
    CrossRef    PMid:16462797    
35. Khattak, A.A., M. Venkatesan, L. Khatoon, A. Ouattara, L.J. Kenefic and M.F. Nadeem, 2013. Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan. Malaria J., 12: 310.
    CrossRef    PMid:24007534 PMCid:PMC3766695    
36. Klein, E.Y., 2012. Antimalarial Drug Resistance. A Dissertation Presented to the Faculty of Princeton University in Candidacy for the Degree of Doctor of Philosophy. Princeton University.
    
37. Klein, E.Y., 2013. Antimalarial drug resistance: A review of the biology and strategies to delay emergence and spread. Int. J. Antimicrob. Agents, 41: 311-317.
    CrossRef    PMid:23394809 PMCid:PMC3610176    
38. Krogstad, D.J., 1987. Efflux of chloroquine from Plasmodium falciparum: Mechanism of chloroquine resistance. Science, 238: 1283-1285.
    CrossRef    PMid:3317830    
39. Lau, Y.L., M.Y. Fong, R. Mahmud, P.Y. Chang, V. Palaeya, F.W. Cheong and L.C. Chin, 2011. Specific, sensitive and rapid detection of human plasmodium knowlesi infection by loop-mediated isothermal amplification (LAMP) in blood samples. Malaria J., 10: 197.
    CrossRef    PMid:21774805 PMCid:PMC3156799    
40. Luzzatto, L., 2010. The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics. Lancet, 376: 739-741.
    CrossRef    
41. Lackritz, E., 1991. Imported Plasmodium falciparum malaria in American travelers to Africa. Implications for prevention strategies. J. Amer. Med. Association, 265: 383-385.
    CrossRef    PMid:1984539    
42. Laufer, M.K., 2009. Monitoring antimalarial drug efficacy: Current challenges. Curr. Infect. Dis. Rep., 11(1): 59-65.
    CrossRef    PMid:19094826 PMCid:PMC2695491    
43. Lee, P.W., D.D. Ji, C.T. Liu and H.S. Rampao, 2012. Application of loop-mediated isothermal amplification for malaria diagnosis during a follow up study in Sao Tome. Malaria J., 11: 408.
    CrossRef    PMid:23217163 PMCid:PMC3528453    
44. Lu, F., B. Wang, J. Cao and J. Sattabongkot, 2012. Prevalence of drug resistance-associated gene mutations in Plasmodium vivax in central China. Korean J. Parasitol., 50(4): 379-384.
    CrossRef    PMid:23230341 PMCid:PMC3514435    
45. Lamar, J., R. Martschinske, G. Tetreault and C. Doud, 2007. Navy Medical Department pocket guide to malaria prevention and control. pp: 1-112.
    
46. Lee, S.J., E. Seo and Y. Cho, 2013. Proposal for a new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference. Int. J. Parasitol. Drugs Drug Resistance, 3: 119-128.
    CrossRef    PMid:24533301 PMCid:PMC3862410    
47. Murray, C.J.L., L.C. Rosenfeld, S.S. Lim, K.G. Andrews, K.J. Foreman and D. Haring, 2012. Global malaria mortality between 1980 and 2010: A systematic analysis. Lancet, 379(9814): 413-431.
    CrossRef    
48. Mathers, C.D., A.D. Lopez and C.J.L. Murray, 2006. The Burden of Disease and Mortality by Condition: Data, Methods and Results for 2001. Global Burden of Disease and Risk Factors. The International Bank for Reconstruction and Development/ The World Bank, pp: 45-240.
    
49. Morassin, B., R. Fabre, A. Berry and J.F. Magnaval, 2002. One year's experience with the polymerase chain reaction as a routine method for the diagnosis of imported malaria. Amer. J. Trop. Med. Hygiene, 66(5): 503-508.
    CrossRef    PMid:12201583    
50. Martin, S.K., A.M. Oduola and W.K. Milhous, 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science, 235: 899-901.
    CrossRef    PMid:3544220    
51. Mahajan, R.C. and F. Umar, 2004. Drug resistance in malaria. J. Vect. Borne Dis., 41: 5.
    
52. Mehlotra, R.K. and P.A. Zimmerman, 2006. Resistance to Antimalarial Drugs: Parasite and Host Genetic Factors. In: Dronamraju, K.R. and P. Arese, (Eds.), Malaria: Genetic and evolutionary aspects. Springer, New York, NY.
    CrossRef    
53. Mideo, N., D.A. Kennedy, J.M. Carlton, J.A. Bailey, J.J. Juliano and A.F. Read, 2013. Ahead of the curve: Next generation estimators of drug resistance in malaria infections. Trends Parasitol., 29(7): 321-328.
    CrossRef    PMid:23746748 PMCid:PMC3694767    
54. Malaria Consortium, 2014. Disease Control and Better Health. United Kingdom, Retrieved form: info@ malariacon sortium. org/ www. malariaconsortium. org. (Accessed on: August 1, 2014).
    Direct Link
55. Mubjer, R.A., A.A. Adeel, M.L. Chance and A.A. Hassan, 2011. Molecular markers of antimalarial drug resistance in Lahj Governorate, Yemen: Baseline data and Implications. Malaria J., 10: 245.
    CrossRef    PMid:21854642 PMCid:PMC3177815    
56. Meshnick, S.R., T.E. Taylor and S. Kamchonwongpaisan, 1996. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. Microbiol. Rev., 60: 301-315.
    PMid:8801435 PMCid:PMC239445    
57. Nzila, A., 2006. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemotherap., 57(6): 1043-1054.
    CrossRef    PMid:16617066    
58. Noedl, H., C. Wongsrichanalai and W.H. Wernsdorfer, 2003. Malaria drug-sensitivity testing: New assays, new perspectives. TRENDS Parasitol., 19: 4.
    CrossRef    
59. Nwaka, S. and A. Hudson, 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug. Discov., 5: 941-955.
    CrossRef    PMid:17080030    
60. Olliaro, P., 2001. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Therapeutics, 89: 207-219.
    CrossRef    
61. Olliaro, P. and T.N. Wells, 2009. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther., 85: 584-595.
    CrossRef    PMid:19404247    
62. Pillay, P., 2006. Malaria and Antimalarials from Plants. University of Pretoria Edn., South Africa, pp: 1-20.
    
63. Paul, E.W., A.P. Alisa and R.M. Steven, 2005. Real-time PCR methods for monitoring antimalarial drug resistance. Trends Parasitol., 21: 278-283.
    CrossRef    PMid:15922249    
64. Petersen, I., R. Eastman and M. Lanzer, 2011. Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Letters, 585: 1551-1562.
    CrossRef    PMid:21530510    
65. Plowe, C.V., 2003. Monitoring antimalarial drug resistance: Making the most of the tools at hand. J. Experimental Biol., 206: 3745-3752.
    CrossRef    PMid:14506209    
66. Price, R.N., 1996. Effects of artemisinin derivatives on malaria transmissiblity. Lancet, 347: 1654-1658.
    CrossRef    
67. Price, R.N., E. Tjitra, C.A. Guerra, S. Yeung, N.J. White and N.M. Anstey, 2007. Vivax malaria: Neglected and not benign. Am. J. Trop. Med. Hyg., 77: 79-87.
    PMid:18165478 PMCid:PMC2653940    
68. Peter, A., A. Winstanley, A. Steven, B. Ward, W. Robert and C.D. Snow, 2002. Current focus Clinical status and implications of antimalarial drug resistance. Microbes Infection, 4: 157-164.
    CrossRef    
69. Robert, V., A.H. Awono, J. Hesran and J. Trape, 2001. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated P. falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. A. J. Trop. Med. Hyg., 62: 210-216.
    CrossRef    
70. Ringwald, P. and L.K. Basco, 1999. Comparison of in vivo and in vitro tests of resistance in patients treated with chloroquinein Yaoundé, Cameroon. Bull. World Health Organiz., 77(1).
    
71. Snow, R.W., C.A. Guerra, A.M. Noor, H.Y. Myint and S.I. Hay, 2005. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature, 434(7030): 214-217.
    CrossRef    PMid:15759000 PMCid:PMC3128492    
72. Shillcutt, S., C. Morel, C. Goodman, P. Coleman, D. Bell, C.J.M. Whitty and A. Mills, 2008. Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. Bull.World Health Organiz., 86(2): 101-110.
    CrossRef    PMid:18297164 PMCid:PMC2647374    
73. Saifi, M.A., T. Beg, A.H. Harrath, F.S. Altayala and S.A. Quraishy, 2012. Antimalarial drugs: Mode of action and status of resistance. Afr. J. Pharm. Pharmacol., 7(5): 148-156.
    CrossRef    
74. Sidhu, A.B., D. Verdier-Pinard and D.A. Fidock, 2002. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science, 298: 210-213.
    CrossRef    PMid:12364805 PMCid:PMC2954758    
75. Shretta, R., J. Omumbo, B. Rapouda and R.W. Snow, 2000. Using evidence to change anti-malarial drug policy in Kenya. Trop. Med. Int. Health, 5: 755-787.
    CrossRef    PMid:11123822    
76. Schlitzer, M., 2008. Antimalarial drugs-what is in use and what is in the pipeline. Arch. Pharm. (Weinheim), 341:149-163.
    CrossRef    PMid:18297679    
77. Sharma, Y.D., 2012. Molecular surveillance of drug-resistant malaria in India. Current Sci., 102: 5.
    
78. Shanks, G.D., 2006. Treatment of falciparum malaria in the age of drug-resistance. J. Postgrad. Med., 52: 277-280.
    PMid:17102546    
79. Talisuna, A.O., C. Karema, B. Ogutu, E. Juma, J. Logedi, A. Nyandigisi, M. Mulenga and et al., 2012. Mitigating the threat of artemisinin resistance in Africa: Improvement of drug-resistance surveillance and response systems. Lancet Infect. Dis., 12: 888-896.
    CrossRef    
80. Thera, M.A. and C.V. Plowe, 2012. Vaccines for Malaria: How Close Are We? Annu. Rev. Med., 63: 345-357.
    CrossRef    PMid:22077719 PMCid:PMC3338248    
81. Trape, J.F., G. Pison, M.P. Preziosi, C. Enel, L.A. Desgrees and et al., 1998. Impact of chloroquine resistance on malaria mortality. C. R. Acad. Sci. III, 321: 689-697.
    CrossRef    
82. Teuscher, F., M.L. Gatton, N. Chen, J. Peters, D.E. Kyle and Q. Cheng, 2010. Artemisinin-induced dormancy in Plasmodium falciparum: Duration, recovery rates and implications in treatment failure. J. Infect. Dis., 202: 1362-1368.
    CrossRef    PMid:20863228 PMCid:PMC2949454    
83. Talisuna, A.O., P.D. Bloland and U. Alessandro, 2004. History, dynamics and public health importance of malaria parasite resistant. Clin. Microbiol. Rev., 17: 235-254.
    CrossRef    PMid:14726463 PMCid:PMC321461    
84. Van, T.D., J.P. Daniel, F.S. Stephen, E.N. Daniel and et al., 2011. Identification and functional validation of the novel antimalarial resistance locus PF10_0355 in Plasmodium falciparum. PLoS Genetics, 7(4): e1001383.
    CrossRef    PMid:21533027 PMCid:PMC3080868    
85. Valderramos, S.G. and D.A. Fidock, 2006. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci., 27: 594-601.
    CrossRef    PMid:16996622 PMCid:PMC2944664    
86. Vernet, G., C. Mary, D.M. Altmann, O. Doumbo, S. Morpeth, Z.A. Bhutta and K.P. Klugman, 2014. Surveillance for antimicrobial drug resistance in under-resourced countries. Emerg. Infectious Dis., 20: 3.
    CrossRef    PMid:24564906 PMCid:PMC3944851    
87. Wang, X., J. Mu, G. Li, P. Chen, X. Guo, L. Fu, L. Chen, X. Su and T.E. Wellems, 2005. Decreased prevalence of the Plasmodium falciparum chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against P. falciparum malaria in Hainan, People's Republic of China. Am. J. Trop. Med. Hyg., 72: 410-414.
    PMid:15827277    
88. Ward, S.A. and I.C. Boulton, 2013. CRIMALDDI: A prioritized research agenda to expedite the discovery of new anti-malarial drugs. Malaria J., 12: 395.
    CrossRef    PMid:24191947 PMCid:PMC3830512    
89. Wernsdorfer, W.H. and D. Payne, 1991. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol. Ther., 50: 95-121.
    CrossRef    
90. Wernsdorfer, W.H., T. Chongsuphajaisiddhi and N.P. Salazar, 1994. A symposium on containment of mefloquine resistant falciparum malaria in Southeast Asia with special reference to border malaria. Southeast Asian J. Trop. Med. Pub. Health, 25: 11-18.
    PMid:7825000    
91. White, N.J., 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial Agents Chemotherap., 41: 413-1422.
    
92. White, N.J., 1999. Averting a malaria disaster. Lancet, 353: 1965-1967.
    CrossRef    
93. White, N.J., 2004. Antimalarial drug resistance. J. Clin. Invest., 113: 1084-1092.
    CrossRef    PMid:15085184 PMCid:PMC385418    
94. White, N.J., 2008. Qinghaosu (artemisinin): The price of success. Science, 320: 330-334.
    CrossRef    PMid:18420924    
95. WHO, 1967. Chemotherapy of malaria. Report of a WHO Scientific Group. Geneva, Switzerland.
    
96. WHO, 1973. Chemotherapy of malaria and resistance to antimalarials. Report of a WHO Scientific Group. WHO Technical Report Series, No. 529. Switzerland, Geneva.
    
97. WHO, 1993. Implementation of the Global Malaria Control Strategy: Report of a WHO Study Group on the implementation of the global plan of action for malaria control 1993-2000. Technical Report Series No. 839.
    
98. WHO, 2001. Department of Communicable Disease Surveillance and Response. Drug resistance in malaria. Retrieved form: http://www.who.int/emc. (Accessed on: May 23/2014).
    Direct Link
99. WHO, 2009. Strategy Paper on Management of Antimalarial Drug Resistance for the Roll Back Malaria (RBM) Board. Retrieved form: http:// apps.who.int/malaria/docs/drugresistance/ Protocol). (Accessed on: July 7, 2014).
    
100. WHO, 2010. Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010.
     
101. WHO, 2011. Global Plan for Artemisinin Resistance Containment. Retrieved form: www.who.int/ malaria/.../atoz/. (Accessed on: June 12, 2014).
     
102. WHO, 2012. World Malaria Report. Geneva, Switzerland.
     
103. WHO, 2013a. Global Report on antimalarial drug efficacy and drug resistance: 2000-2010.
     
104. WHO, 2013b. Antimalarial drug resistance. The World Health Organization, Last Update: 2013. Geneva, Switzerland.
     
105. WHO, 2014. Status Report on Artemisinin Resistance. January, 2014. (July 18, 2014).
     
106. WHO, 2013c. Emergency response to artemisinin resistance in the Greater Mekong Sub region.
     
107. Wells, T.N.C., P.L., Alonso and W.E. Gutteridge, 2009. New medicines to improve control and contribute to the eradication of malaria. Nature Rev. Drug Discovery, 8: 879.
     CrossRef    PMid:19834482    
108. Yusuf, R.U., S.A. Omar and R.M. Ngure, 2010. The effect of Point Mutations in Dihydrofolate reductase genes and the Multidrug resistance gene 1-86 on treatment of falciparum malaria in Sudan. J. Infect. Dev. Ctries., 4(2): 61-69.
     CrossRef    PMid:20212335    

Competing interests

The authors have no competing interests.

Open Access Policy

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright

The authors have no competing interests.